



LBDA

LEWY BODY DEMENTIA ASSOCIATION

RESEARCH CENTERS OF EXCELLENCE

Publication List July 2022 – July 2023

LBDA supported research and activities

1. Bayram E, Holden SK, Fullard M, Armstrong MJ; Lewy Body Dementia Association Community Engagement Working Group. Race and Ethnicity in Lewy Body Dementia: A Narrative Review [published online ahead of print, 2023 Jun 19]. *J Alzheimers Dis*. 2023;10.3233/JAD-230207. doi:10.3233/JAD-230207
2. Chiu SY, Wyman-Chick KA, Ferman TJ, Bayram E, Holden SK, Choudhury P, Armstrong MJ. Sex differences in dementia with Lewy bodies: Focused review of available evidence and future directions. *Parkinsonism Relat Disord*. 2023 Feb;107:105285. doi: 10.1016/j.parkreldis.2023.105285. Epub 2023 Jan 16. PMID: 36682958
3. Sabbagh MN, Taylor A, Galasko D, Galvin JE, Goldman JG, Leverenz JB, Poston KL, Boeve BF, Irwin DJ, Quinn JF. Listening session with the US Food and Drug Administration, Lewy Body Dementia Association, and an expert panel. *Alzheimers Dement (N Y)*. 2023 Feb 8;9(1):e12375. doi: 10.1002/trc2.12375. PMID: 36873923; PMCID: PMC9983146.
4. Holden SK, Bedenfield N, Taylor AS, Bayram E, Schwilk C, Fleisher J, Duda J, Shill H, Paulson HL, Stacy K, Wood J, Corsentino P, Sha SJ, Litvan I, Irwin DJ, Quinn JF, Goldman JG, Amodeo K, Taylor JP, Boeve BF, Armstrong MJ. Research Priorities of Individuals and Caregivers With Lewy Body Dementia: A Web-based Survey. *Alzheimer Dis Assoc Disord*. 2023 Jan-Mar 01;37(1):50-58. doi: 10.1097/WAD.0000000000000545. Epub 2023 Feb 23. PMID: 36821177; PMCID: PMC9971616.
5. Bayram, E., Coughlin, D. G., & Litvan, I. Sex Differences for Clinical Correlates of Alzheimer's Pathology in People with Lewy Body Pathology. *Movement disorders : official journal of the Movement Disorder Society*, 2022. 37(7), 1505–1515. <https://doi.org/10.1002/mds.29044>

Additional research in dementia with Lewy bodies, Parkinson's disease with dementia, and Lewy body disease

1. Reho P, Koga S, Shah Z, Chia R; International LBD Genomics Consortium; American Genome Center, Rademakers R, Dalgard CL, Boeve BF, Beach TG, Dickson DW, Ross OA, Scholz SW. GRN Mutations Are Associated with Lewy Body Dementia. *Mov Disord*. 2022 Jul 10. doi: 10.1002/mds.29144. Epub ahead of print. PMID: 35810449.
2. Valentino RR, Ramnarine C, Heckman MG, Johnson PW, Soto-Beasley AI, Walton RL, Koga S, Kasanuki K, Murray ME, Uitti RJ, Fields JA, Botha H, Ramanan VK, Kantarci K, Lowe VJ, Jack CR, Ertekin-Taner N, Savica R, Graff-Radford J, Petersen RC, Parisi JE, Reichard RR, Graff-Radford NR, Ferman TJ, Boeve BF, Wszolek ZK, Dickson DW, Ross OA. Mitochondrial genomic variation in dementia with Lewy bodies: association with disease risk and neuropathological measures. *Acta Neuropathol Commun*. 2022 Jul 14;10(1):103. doi: 10.1186/s40478-022-01399-4. PMID: 35836284; PMCID: PMC9281088.
3. Toledo JB, Abdelnour C, Weil RS, Ferreira D, Rodriguez-Porcel F, Pilotto A, Wyman-Chick KA, Grothe MJ, Kane JPM, Taylor A, Rongve A, Scholz S, Leverenz JB, Boeve BF, Aarsland D, McKeith IG, Lewis S, Leroi I, Taylor JP; ISTAART Lewy body dementias Trial Methods Working Group. Dementia with Lewy bodies: Impact of co- pathologies and implications for clinical trial design. *Alzheimers Dement*. 2023 Jan;19(1):318-332. doi: 10.1002/alz.12814. Epub 2022 Oct 14. PMID: 36239924.
4. O'Brien JT, Chouliaras L, Sultana J, Taylor JP, Ballard C; RENEWAL Study Group (Boeve BF – member). RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia-an international Delphi consensus. *Alzheimers Res Ther*. 2022 Nov 11;14(1):169. doi: 10.1186/s13195-022-01103-7. PMID: 36369100; PMCID: PMC9650797.
5. Ferreira D, Przybelski SA, Lesnick TG, Schwarz CG, Diaz-Galvan P, Graff- Radford J, Senjem ML, Fields JA, Knopman DS, Jones DT, Savica R, Ferman TJ, Graff-Radford N, Lowe VJ, Jack CR, Petersen RC, Westman E, Boeve BF, Kantarci K. Cross-sectional Associations of β -Amyloid, Tau, and Cerebrovascular Biomarkers With Neurodegeneration in Probable Dementia With Lewy Bodies. *Neurology*. 2022 Nov 28;10.1212/WNL.0000000000201579. doi: 10.1212/WNL.0000000000201579. Epub ahead of print. PMID: 36443011.
6. Somerville EN, Krohn L, Yu E, Rudakou U, Senkevich K, Ruskey JA, Asayesh F, Ahmad J, Spiegelman D, Dauvilliers Y, Arnulf I, Hu MTM, Montplaisir JY, Gagnon JF, Desautels A, Ibrahim A, Stefani A, Högl B, Gigli GL, Valente M, Janes F, Bernardini A, Dusek P, Sonka K, Kemlink D, Plazzi G, Antelmi E, Biscarini F, Mollenhauer B, Trenkwalder C, Sixel-Doring F, Figorilli M, Puligheddu M, De Cock VC, Oertel W, Janzen A, Ferini-Strambi L, Heibreder A, Monaca CC, Abril B, Dijkstra F, Viaene M, Boeve BF, Postuma RB, Rouleau GA, Gan-Or Z. NPC1 variants are not associated with Parkinson's disease, REM-sleep behavior disorder or dementia with Lewy bodies in European cohorts. *Neurobiol Aging*. 2023 Jul;127:94-98. doi: 10.1016/j.neurobiolaging.2023.03.002. Epub 2023 Mar 8. PMID: 37032242.
7. Habich A, Oltra J, Schwarz CG, Przybelski SA, Oppedal K, Inguanzo A, Blanc F, Lemstra AW, Hort J, Westman E, Lowe VJ, Boeve BF, Dierks T, Aarsland D, Kantarci K, Ferreira D. Sex differences in grey matter networks in dementia with Lewy bodies. *Res Sq [Preprint]*. 2023 Jan 30:rs.3.rs-2519935. doi: 10.21203/rs.3.rs-2519935/v1. PMID: 36778448; PMCID: PMC9915801.
8. Yu E, Krohn L, Ruskey JA, Asayesh F, Spiegelman D, Shah Z, Chia R, Arnulf I, Hu MTM, Montplaisir JY, Gagnon JF, Desautels A, Dauvilliers Y, Gigli GL, Valente M, Janes F, Bernardini A, Högl B, Stefani A, Ibrahim A, Heibreder A, Sonka K, Dusek P, Kemlink D, Oertel W, Janzen A, Plazzi G, Antelmi E, Figorilli M, Puligheddu M, Mollenhauer B, Trenkwalder C, Sixel-Döring F, Cochen De Cock V, Ferini-Strambi L, Dijkstra F, Viaene M,

- Abril B, Boeve BF, Rouleau GA, Postuma RB, Scholz SW; International LBD Genomics Consortium; Gan-Or Z. HLA in isolated REM sleep behavior disorder and Lewy body dementia. *Ann Clin Transl Neurol.* 2023 Jul 4. doi: 10.1002/acn3.51841. Epub ahead of print. PMID: 37401389.
9. Oltra J, Habich A, Schwarz CG, Nedelska Z, Przybelski SA, Inguanzo A, Diaz-Galvan P, Lowe VJ, Oppedal K, Blanc F, Lemstra AW, Hort J, Padovani A, Rektorova I, Bonanni L, Massa F, Kramberger MG, Taylor JP, Snædal J, Walker Z, Antonini A, Segura B, Junque C, Westman E, Boeve BF, Aarsland D, Kantarci K, Ferreira D. Sex differences in brain atrophy in dementia with Lewy bodies. *Res Sq [Preprint]*. 2023 Jan 27:rs.3.rs-2516427. doi: 10.21203/rs.3.rs-2516427/v1. PMID: 36747755; PMCID: PMC9901042.
 10. Pavuluri K, Scott JM, Huston Iii J, Ehman RL, Manduca A, Jack CR Jr, Savica R, Boeve BF, Kantarci K, Petersen RC, Knopman DS, Murphy MC. Differential effect of dementia etiology on cortical stiffness as assessed by MR elastography. *Neuroimage Clin.* 2023;37:103328. doi: 10.1016/j.nicl.2023.103328. Epub 2023 Jan 18. PMID: 36696808; PMCID: PMC9879983.
 11. Inguanzo A, Poulakis K, Mohanty R, Schwarz CG, Przybelski SA, Diaz-Galvan P, Lowe VJ, Boeve BF, Lemstra AW, van de Beek M, van der Flier W, Barkhof F, Blanc F, Loureiro de Sousa P, Philippi N, Cretin B, Demuynck C, Nedelska Z, Hort J, Segura B, Junque C, Oppedal K, Aarsland D, Westman E, Kantarci K, Ferreira D. MRI data-driven clustering reveals different subtypes of Dementia with Lewy bodies. *NPJ Parkinsons Dis.* 2023 Jan 20;9(1):5. doi: 10.1038/s41531-023-00448-6. PMID: 36670121; PMCID: PMC9859778.
 12. Diaz-Galvan P, Przybelski SA, Lesnick TG, Schwarz CG, Senjem ML, Gunter JL, Jack CR, Min HP, Jain M, Miyagawa T, Forsberg LK, Fields JA, Savica R, Graff-Radford J, Jones DT, Botha H, St Louis EK, Knopman DS, Ramanan VK, Ross O, Graff-Radford N, Day GS, Dickson DW, Ferman TJ, Petersen RC, Lowe VJ, Boeve BF, Kantarci K. β -Amyloid Load on PET Along the Continuum of Dementia With Lewy Bodies. *Neurology.* 2023 Jul 11;101(2):e178-e188. doi: 10.1212/WNL.0000000000207393. Epub 2023 May 18. PMID: 37202168; PMCID: PMC10351554.
 13. Kaivola K, Chia R, Ding J, Rasheed M, Fujita M, Menon V, Walton RL, Collins RL, Billingsley K, Brand H, Talkowski M, Zhao X, Dewan R, Stark A, Ray A, Solaiman S, Alvarez Jerez P, Malik L, Dawson TM, Rosenthal LS, Albert MS, Pletnikova O, Troncoso JC, Masellis M, Keith J, Black SE, Ferrucci L, Resnick SM, Tanaka T; American Genome Center; International LBD Genomics Consortium; International ALS/FTD Consortium; PROSPECT Consortium; Topol E, Torkamani A, Tienari P, Foroud TM, Ghetti B, Landers JE, Ryten M, Morris HR, Hardy JA, Mazzini L, D'Alfonso S, Moglia C, Calvo A, Serrano GE, Beach TG, Ferman T, Graff-Radford NR, Boeve BF, Wszolek ZK, Dickson DW, Chiò A, Bennett DA, De Jager PL, Ross OA, Dalgard CL, Gibbs JR, Traynor BJ, Scholz SW. Genome-wide structural variant analysis identifies risk loci for non-Alzheimer's dementias. *Cell Genom.* 2023 May 4;3(6):100316. doi: 10.1016/j.xgen.2023.100316. PMID: 37388914; PMCID: PMC10300553.
 14. Townsend LTJ, Anderson KN, Boeve BF, McKeith I, Taylor JP. Sleep disorders in Lewy body dementia: Mechanisms, clinical relevance, and unanswered questions. *Alzheimers Dement.* 2023 Jul 1. doi: 10.1002/alz.13350. Epub ahead of print. PMID: 37392199.
 15. Arnold MR, Coughlin DG, Brumbach BH, Smirnov DS, Concha-Marambio L, Farris CM, Ma Y, Kim Y, Wilson EN, Kaye JA, Hiniker A, Woltjer RL, Galasko DR, Quinn JF. α -Synuclein Seed Amplification in CSF and Brain from Patients with Different Brain Distributions of Pathological α -Synuclein in the Context of Co-Pathology and NonLBD Diagnoses. *Ann Neurol.* 2022 Oct;92(4):650-662. doi: 10.1002/ana.26453. Epub 2022 Jul 29. PMID: 35808984
 16. Shahid M, Rawls A, Ramirez V, Ryman S, Santini V, Yang L, Sha S, Hall J, Montine T, Lin A, Tian L, Henderson V, Cholerton B, Yutsis M, Poston K. Illusory responses across the

- Lewy body disease spectrum. *Ann Neurol*; 2022 Dec 13. doi: 10.1002/ana.26574. PMID: 36511519
17. Skylar-Scott I, Sha SJ. Lewy Body Dementia: An Overview of Promising Therapeutics. *Current Neurology and Neuroscience Reports*. 2023, in press
 18. Andersen KB, Hansen AK, Schacht AC, Horsager J, Gottrup H, Klit H, Danielsen EH, Poston KL, Pavese N, Brooks DJ, Borghammer P. Synaptic Density and Glucose Consumption in Patients with Lewy Body Diseases: An [11 C]UCB-J and [18 F]FDG PET Study. *Mov Disord*. 2023 Mar 11. PMID: 36905188.
 19. Abdelnour C, Gonzalez MC, Gibson LL, Poston KL, Ballard CG, Cummings JL, Aarsland D. Dementia with Lewy Bodies Drug Therapies in Clinical Trials: Systematic Review up to 2022. *Neurol Ther*. 2023 Jun;12(3):727-749. doi: 10.1007/s40120-023-00467-8. Epub 2023 Apr 5. PMID: 37017910; PMCID: PMC10195935.
 20. Salmon, D. P., Smirnov, D. S., Coughlin, D. G., Hamilton, J. M., Landy, K. M., Filoteo, J. V., Hiniker, A., Hansen, L. A., & Galasko, D. (2022). Perception of Fragmented Letters by Patients With Pathologically Confirmed Dementia With Lewy Bodies or Alzheimer Disease. *Neurology*, 2022. 99(18), e2034–e2043. <https://doi.org/10.1212/WNL.0000000000201068>
 21. Wylie KP, Kluger BM, Medina LD, Holden SK, Kronberg E, Tregellas JR, Buard I. Hippocampal, basal ganglia and olfactory connectivity contribute to cognitive impairments in Parkinson's disease. *The European Journal of Neuroscience*. 2023 Feb;57(3):511-526.
 22. Carlisle T, Fought AJ, Olson KE, Lopez-Esquivel N, Simpson A, Medina LD, Holden SK. Longitudinal evaluation of cognitively demanding daily function using performance-based functional assessment highlights heterogeneous trajectories in cognitive and functional abilities in people with Parkinson's disease. *Frontiers in Neuroscience: Neurodegeneration*. 2023 Jun 26;17:1200347.
 23. Walker IM, Cousins KA, Siderowf A, Duda JE, Morley JF, Dahodwala N, Tropea T, Vaishnavi S, Wolk DA, Chen-Plotkin AS, Shaw LM, Lee EB, Trojanowski JQ, Grossman M, Weintraub D, Irwin DJ. Non-tremor motor dysfunction in Lewy body dementias is associated with AD biomarkers. *Parkinsonism Relat Disord*. 2022 Jul;100:33-36. doi:10.1016/j.parkreldis.2022.05.022. Epub 2022 Jun 8. PMID:35700626; PMCID: PMC10078247
 24. Shellikeri S, Cho S, Cousins KAQ, Liberman M, Howard E, Balganorth Y, Weintraub D, Spindler M, Deik A, Lee EB, Trojanowski JQ, Irwin D, Wolk D, Grossman M, Nevler N. Natural speech markers of Alzheimer's disease co-pathology in Lewy body dementias. *Parkinsonism Relat Disord*. 2022 Sep; 102:94-100. doi:10.1016/j.parkreldis.2022.07.023. Epub 2022 Aug 6. PMID: 35985146; PMCID: PMC9680016.
 25. Weintraub D, Irwin D. Diagnosis and Treatment of Cognitive and Neuropsychiatric Symptoms in Parkinson Disease and Dementia With Lewy Bodies. *Continuum (Minneapolis, Minn)*. 2022 Oct 1; 28(5):1314-1332. doi:10.1212/CON.0000000000001151. PMID: 36222767.
 26. Cousins KAQ, Irwin DJ, Chen-Plotkin A, Shaw LM, Arezoumandan S, Lee EB, Wolk DA, Weintraub D, Spindler M, Deik A, Grossman M, Tropea TF. Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease. *Ann Clin Transl Neurol*. 2023 May;10(5):802-813. doi: 10.1002/acn3.51768. Epub 2023 Mar 31. PMID: 37000892; PMCID: PMC10187730.
 27. Tropea TF, Albuja I, Cousins KAQ, Irwin DJ, Lee EB, Chen-Plotkin AS. Concomitant Alzheimer Disease Pathology in Parkinson Disease Dementia. *Ann Neurol*. 2023 May;93(5):1045-1046. doi: 10.1002/ana.26635. Epub 2023 Mar 16. PMID: 36892304; PMCID: PMC10192049.
 28. Choudhury P, Zhang Z, Adler CH, Chen K, Belden C, Driver-Dunckley E, Mehta SH, Shprecher DR, Serrano G, Shill HA, Beach TG, and Atri A. Longitudinal motor decline in

- Dementia with Lewy Bodies, Parkinson Disease Dementia, and Alzheimer's dementia in a community autopsy cohort. *Alzheimer's Dement* 2023; 1-11. DOI: 10.1002/alz.13357
29. Huddleston DE, Langley J, Chen X, John S, Littrell K, Tucker K, Hu X. Imaging neuromelanin and iron pathology in vivo in neurodegenerative parkinsonism. *Annals of Neurology*. (2022) Oct; 92(S29): S128. doi: 10.1002/ana/26484
 30. Hess SP, Levin M, Akram F, Woo K, Andersen L, Trenkle K, Brown P, Ouyang B, Fleisher JE. The Impact and Feasibility of a Brief, Virtual, Educational Intervention for Home Healthcare Professionals on Parkinson's Disease and Related Disorders: Pilot Study of I SEE PD Home. *BMC Med Educ* 22, 506 (2022). <https://doi.org/10.1186/s12909-022-03430-7>
 31. Fleisher JE, Moshkovich A, Levin M, Akram F, Hess SP, Suresh M, Bentley CD, Manak T, Mattke M, Miller A, Pennsylv CE, Pierce CM, Voss M, Taylor A, Schroeder K, Chodosh J. Family Caregiver Comorbidities in Lewy Body Dementia Versus Alzheimer Disease and Associated Disorders. *Alzheimer Dis Assoc Disord*. 2023 Jan-Mar 01;37(1):42-49. doi: 10.1097/WAD.0000000000000535. Epub 2022 Nov 9. PMID: 36346930.
 32. Fleisher JE, Suresh M, Levin ME, Hess SP, Akram F, Dodson D, Tosin M, Stebbins GT, Woo K, Ouyang B, Chodosh J. Learning to PERSEVERE: A pilot study of peer mentor support and caregiver education in Lewy body dementia. *Parkinsonism Relat Disord*. 2023 Jun 24;113:105492. doi: 10.1016/j.parkreldis.2023.105492. Epub ahead of print. PMID: 37385161.
 33. Jain L, Khrestian M, Formica S, Tuason ED, Pillai JA, Rao S, Oguh O, Lippa CF, Lopez OL, Berman SB, Tsuang DW, Zabetian CP, Irwin DJ, Galasko DR, Litvan I, Marder KS, Honig LS, Fleisher JE, Galvin JE, Bozoki AC, Taylor AS, Sabbagh MN, Wint D, Leverenz JB, Bekris LM. ATN cerebrospinal fluid biomarkers in Dementia with Lewy Bodies: Initial results from the United States Dementia with Lewy Bodies Consortium. Accepted for publication, *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, 2023.
 34. Constant, A. B., Basavaraju, R., France, J., Honig, L. S., Marder, K. S., & Provenzano, F. A. Longitudinal Patterns of Cortical Atrophy on MRI in Patients With Alzheimer Disease With and Without Lewy Body Pathology. *Neurology*, 2022. 99(17), e1843-1852. <https://doi.org/10.1212/WNL.0000000000200947>
 35. Pantelyat A, Dayanim G, Kang K, Turk B, Pagkatipunan R, Huenergard SK, Mears A, Bang J. Rhythmic auditory cueing in atypical parkinsonism: A pilot study. *Front Neurol*. 2022 Oct 28;13:1018206. doi: 10.3389/fneur.2022.1018206. PMID: 36388209; PMCID: PMC9650086.
 36. Wollney EN, Armstrong MJ, Bedenfield N, Rosselli M, Curiel-Cid RE, Kitaigorodsky M, Levy X, Bylund CL. Barriers and Best Practices in Disclosing a Dementia Diagnosis: A Clinician Interview Study. *Health Serv Insights*. 2022;15:11786329221141829. Published 2022 Dec 5. doi:10.1177/11786329221141829
 37. Kurasz AM, De Wit L, Smith GE, Armstrong MJ. Neuropathological and clinical correlates of Lewy body disease survival by race and ethnicity in the National Alzheimer's Coordinating Center. *J Alzheimers Dis* 2022; 89:1339-1349. doi: 10.3233/JAD-220297
 38. McFarland N. Clinical features and diagnosis of dementia with Lewy bodies. UpToDate (literature review current through June 2023).
 39. McFarland N. Prognosis and treatment of dementia with Lewy bodies. UpToDate (literature review current through June 2023).
 40. Pillai JA, Bena J, Maly EF, Leverenz JB. Initial non-amnestic symptoms relate to faster rate of functional and cognitive decline compared to amnestic symptoms in neuropathologically confirmed dementias. *Alzheimers Dement*. 2023 Jan 17:10.1002/alz.12922. doi: 10.1002/alz.12922. Epub ahead of print. PMID: 36648159; PMCID: PMC10350479.

41. MacDonald S, Shah AS, Tousi B. Current Therapies and Drug Development Pipeline in Lewy Body Dementia: An Update. *Drugs Aging*. 2022 Jul;39(7):505-522. doi: 10.1007/s40266-022-00939-w. Epub 2022 May 27. PMID: 35619045.
42. Collerton D, Barnes J, Diederich NJ, Dudley R, Ffytche D, Friston K, Goetz CG, Goldman JG, Jardri R, Kulisevsky J, Lewis SJG, Nara S, O'Callaghan C, Onofrj M, Pagonabarraga J, Parr T, Shine JM, Stebbins G, Taylor JP, Tsuda I, Weil RS. Understanding visual hallucinations: A new synthesis. *Neurosci Biobehav Rev*. 2023 Jul;150:105208. doi: 10.1016/j.neubiorev.2023.105208. Epub 2023 May 2. PMID: 37141962.
43. Moon S, Kletzel SL, Santos FH, Devos H, Foster ER, Goldman JG, Hirsch MA, Leroi I, Walker S, York MK. A Patient's Guide to Memory Changes in Parkinson Disease. *Arch Phys Med Rehabil*. 2023 May 31:S0003-9993(23)00286-1. doi: 10.1016/j.apmr.2023.01.027. Epub ahead of print. PMID: 37256244.
44. Weintraub D, Aarsland D, Biundo R, Dobkin R, Goldman J, Lewis S. Management of psychiatric and cognitive complications in Parkinson's disease. *BMJ*. 2022 Oct 24;379:e068718. doi: 10.1136/bmj-2021-068718. PMID: 36280256.
45. Goldman JG, Holden SK. Cognitive Syndromes Associated With Movement Disorders. *Continuum (Minneap Minn)*. 2022;28(3):726-749. doi: 10.1212/CON.0000000000001134. PMID: 35678400.
46. Donaghy PC, Carrarini C, Ferreira D, Habich A, Aarsland D, Babioloni C, Bayram E, Kane JPM, Lewis SJG, Pilotto A, Thomas AJ, Bonanni L on behalf of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment Lewy Body Dementias Prodromal Working Group. Research diagnostic criteria for mild cognitive impairment with Lewy bodies: a systematic review and meta-analysis. *Alzheimers Dement*. 2023 Apr 24. doi: 10.1002/alz.13105

Additional clinical research related to other LBD-related neurodegenerative disorders (e.g., Parkinson's disease, REM sleep behavior disorder, dementia, etc.)

1. Weston L.J., Bowman A.M., Osterberg V.R., Meshul C.K., Woltjer R.L., Unni V.K. Aggregated Alpha-Synuclein Inclusions within the Nucleus Predict Impending Neuronal Cell Death in a Mouse Model of Parkinsonism. *International Journal of Molecular Science* 2022 Dec 4;23(23):15294. doi: 10.3390/ijms232315294. PMID: 36499619
2. Weintraub D, Picillo M, Cho HR, Caspell-Garcia C, Blauwendraat C, Brown EG, Chahine LM, Coffey CS, Dobkin RD, Foroud T, Galasko D, Kiebertz K, Marek K, Merchant K, Mollenhauer B, Poston KL, Simuni T, Siderowf A, Singleton A, Seibyl J, Tanner CM; Parkinson's Progression Markers Initiative. Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory Study. *Mov Disord Clin Pract*. 2023 Apr 25;10(6):943-955. doi: 10.1002/mdc3.13751. PMID: 37332638; PMCID: PMC10272925.
3. Hwang KS, Langley J, Tripathi R, Hu XP, Huddleston DE. In vivo detection of substantia nigra and locus coeruleus volume loss in Parkinson's disease using neuromelanin-sensitive MRI: Replication in two cohorts. *PLoS One*. 2023 Apr 13;18(4):e0282684. PMID: 37053195. doi: 10.1371/journal.pone.0282684
4. Cook, L., Verbrugge, J., Schwantes-An, T. H., Schulze, J., Beck, J. C., Naito, A., Hall, A., Chan, A. K., Casaceli, C. J., Marder, K., Nance, M., Schwarzschild, M. A., Simuni, T., Wills, A. M., Alcalay, R. N., Parkinson's, F., & Parkinson's Study, G. Providing Genetic Testing and Genetic Counseling for Parkinson's Disease to the Community. *Genet Med*. 2023 <https://doi.org/10.1016/j.gim.2023.100907>

5. Saunders-Pullman, R., Raymond, D., Ortega, R. A., Shalash, A., Gatto, E., Salari, M., Markgraf, M., Alcalay, R. N., Mascalzoni, D., Mencacci, N. E., T., . . . Simuni, T. (2023). International Genetic Testing and Counseling Practices for Parkinson's Disease. *Mov Disord*. <https://doi.org/10.1002/mds.29442>
6. Besser LM, Jimenez MP, Reimer CJ, Meyer OL, Mitsova D, George KM, Adkins' Jackson PB, Galvin JE. Diversity of studies on neighborhood greenspace and brain health by racialized/ethnic group and geographic region: A rapid review. *Int J Environ Res Public Health* 20:5666; 2023 (PMCID: 10178609)
7. Besser LM, Meyer OL, Streitz M, Farias ST, Olichney J, Mitsova D, Galvin JE. Perceptions of greenspace and social determinants of health across the life course: The Life Course Sociodemographics and Neighborhood Questionnaire (LSNEQ). *Health Place* 81:103008;2023.
8. Boltz M, Kuzmik A, Resnick B, Belue R, Jao Y-L, Paudel A, Behrens L, Leslie D, Sinvani L, Galvin JE. Delirium and behavioral symptoms in hospitalized persons with dementia. *Alz Dis Assoc Disord*, 37:120-127,2023.
9. Tolea MI, Camacho S, Cohen IR, Galvin JE. Mindfulness and care experience in family caregivers of persons living with dementia. *J Alzheimers Dis Rep* 2023, 7:151-141 (PMCID:9986707).
10. O'Shea DM, Galvin JE. Female APOE ϵ 4 carriers with slow rates of biological aging have better memory performances compared to female E4 carriers with accelerated aging. *J Alzheimers Dis* 92:1269-1282; 2023
11. Fonseca LM, Chaytor NS, Olufadi Y, Buchwald D, Galvin JE, Schmitter-Edgecombe M, Suchy-Dicey A. Intraindividual cognitive variability and magnetic resonance imaging in aging American Indians: Data from the Strong Heart Study. *J Alzheimer Dis*, 91:1395-1407,2023 (PMCID: 9974814)
12. O'Shea DM, Alaimo H, Davis JD, Galvin JE, Tremont G. A comparison of cognitive performances based on differing rates of DNA methylation GrimAge acceleration among older men and women. *Neurobiol Aging*. 2022 Dec 30;123:83-91
13. Liu C, Lee SH, Loewenstein DA, Galvin JE, Levin BE, McKinney A, Alperin N. Early amnesic mild cognitive impairment is associated with reduced total cerebral blood flow with no brain tissue loss. *J Alzheimers Dis* 91:1313-1322,2023.
14. Kleiman MJ, Ariko T, Galvin JE. Hierarchical two-stage cost-sensitive clinical decision support system for screening prodromal Alzheimer's disease and related dementias. *J Alzheimer Dis* 91:895-909; 2023.
15. Daniel EV, Kleiman MJ, Galvin JE. Exploring reasons for differential vulnerability and Alzheimer's disease risk in racial and ethnic minorities. *J Alzheimer Dis*, 91:495-506, 2022
16. Mirabnahrzham G, Ma D, Beaulac C, Lee S, Popuri K, Lee H, Cao J, Galvin JE, Wang L, Beg MF, and the Alzheimer's Disease Neuroimaging Initiative. Predicting time-to-conversion for dementia of Alzheimer's type using multi-modal deep survival analysis. *Neurobiol Aging*, 121:139-159, 2022.
17. Kleiman MJ, Chang LC, Galvin JE. The brain health platform: Combining resilience, vulnerability, and performance to assess brain health and risk of Alzheimer's disease and related disorders. *J Alzheimer Dis*, 90:1817-1830, 2022
18. Pourshams M, Galvin JE, Afshar PF, Santos PG, Bazargan-Hejazi S, Kamalzadeh L, Shariati B, Malakouti SK. Validity and reliability of the Farsi version of the ascertain dementia 8-item (AD8-F) informant interview in Iranian patients with mild neurocognitive disorder. *BMC Geriatr* 22:801, 2022 (PMCID: 9569081)
19. Kleiman MJ, Plewes AD, Owora A, Burkhardt AS, Grout RW, Dexter PR, Fowler N, Galvin JE, Ben Miled Z, Boustani M. Digital detection of dementia (D3): A pragmatic cluster-randomized trial examining the application of patient-reported outcomes. *Trials*, 23:868, 2022 (PMCID: 9552361)

20. Joshi MS, Galvin JE. Cognitive resilience in brain health and dementia research. *J Alzheimer Dis*, 90:461-473, 2022.
21. Avey JP, Schaefer KR, Noonan CJ, Muller CH, Mosely M, Galvin JE. Patterns of healthcare use and mortality after Alzheimer's disease or related dementia diagnosis among Alaskan Native patients: Results of a cluster analysis in a Tribal healthcare setting. *J Alzheimer Dis Rep*, 6:401-410; 2022 (PMCID:9397889)
22. Pang M, Zhu L, Gabelle A, Gafson AR, Platt RW, Galvin JE, Krolak-Salmon P, Rubino I, de Moor C, Belachew S, Shen C. Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: an instrumental variable meta-analysis. *Alzheimer Dement*, 19:1292-1299; 2023.
23. Kuzmik A, Boltz M, Resnick B, Mogle J, BeLue R, Galvin JE. Factors associated with sleep quality in hospitalized persons with dementia. *Alz Dis Assoc Disord*, 36:253-258; 2022
24. Park JY, Galvin JE. Factor structure of the Pre-Loss Grief-12 in caregivers of people living with dementia. *Alzheimers Dementia TRCI*, 8:e12322, 2022 (PMCID: 9270640)
25. Kuzmik A, Boltz M, Belue R, Resnick B, Scott J, Mogle J, Leslie D, Galvin JE. The Modified Caregiver Strain Index in Black and White Dementia Caregivers at Hospital Discharge. *Clin Gerontol*, 46:574-584;2023
26. Resnick B, Boltz M, Kuzmik A, Galik E, Galvin JE. Reliability and validity of the neuropsychiatric inventory questionnaire using a Rasch analysis. *J Nurs Meas 2022 JNM-2021-008.R2* [Online ahead of print]
27. Besser LM, Meyer OL, Jones MR, Tran D, Booker M, Mitsova D, Peterson R, Galvin JE, Bateman JR, Hayden K, Hughes TM. Neighborhood segregation and cognitive change: Multi-Ethnic Study of Atherosclerosis. *Alzheimers Dementia*, 19:1143-1151; 2023
28. Aschenbrenner AJ, Hassenstab J, Wang G, Li Y, Xiong C, McDade E, Clifford D, Salloway S, Farlow M, Yaari R, Cheng EY-J, Holdridge K, Mummery C, Masters CL, Hsiung G-Y, Gauthier S, Surti G, Day G, Weintraub S, Honig L, Galvin JE, Ringman JM, Brooks WS, Fox N, Snyder P, Suzuki K, Shimada H, Jucker M, Bateman R for the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU). Avoid or Embrace? Practice effects in Alzheimer's disease prevention trials. *Front Aging Neurosci*, 14:883131, 2022 (PMCID: 9244171)
29. Seifallahi M, Mehaban AH, Galvin JE, Ghoraani B. Alzheimer's Disease detection using comprehensive analysis of Timed Up and Go test via Kinect V.2 camera and machine learning. *IEEE Tans Neural Syst Rehabil Eng* 30:1589-1600, 2022
30. Mirabnahrzham G, Ma D, Lee S, Popuri K, Lee H, Cao J, Wang L, Galvin JE, Beg MF, and the Alzheimer's Disease Neuroimaging Initiative. Machine learning based multi-modal neuroimaging genomics dementia score for predicting future conversion to Alzheimer's disease. *J Alzheimer Dis*, 87:1345-1365, 2022 (PMCID: 9195128)
31. Gossard TR, Teigen LN, Yoo S, Timm PC, Jagielski J, Bibi N, Feemster JC, Steele T, Carvalho DZ, Junna MR, Lipford MC, Tippmann Peikert M, LeClair-Visonneau L, McCarter SJ, Boeve BF, Silber MH, Hirsch J, Sharp RR, St Louis EK. Patient values and preferences regarding prognostic counseling in isolated REM sleep behavior disorder. *Sleep*. 2023 Jan 11;46(1):zsac244. doi: 10.1093/sleep/zsac244. PMID: 36259668; PMCID: PMC9832520.
32. Levendowski DJ, Walsh CM, Boeve BF, Tsuang D, Hamilton JM, Salat D, Berka C, Lee-Iannotti JK, Shprecher D, Westbrook PR, Mazeika G, Yack L, Payne S, Timm PC, Neylan TC, St Louis EK. Non-REM sleep with hypertonia in Parkinsonian Spectrum Disorders: A pilot investigation. *Sleep Med*. 2022 Dec;100:501-510. doi: 10.1016/j.sleep.2022.09.025. Epub 2022 Oct 4. PMID: 36274383.
33. Krohn L, Heilbron K, Blauwendraat C, Reynolds RH, Yu E, Senkevich K, Rudakou U, Estiar MA, Gustavsson EK, Brolin K, Ruskey JA, Freeman K, Asayesh F, Chia R, Arnulf I, Hu MTM, Montplaisir JY, Gagnon JF, Desautels A, Dauvilliers Y, Gigli GL, Valente M,

- Janes F, Bernardini A, Högl B, Stefani A, Ibrahim A, Šonka K, Kemlink D, Oertel W, Janzen A, Plazzi G, Biscarini F, Antelmi E, Figorilli M, Puligheddu M, Mollenhauer B, Trenkwalder C, Sixel-Döring F, Cochen De Cock V, Monaca CC, Heidebreder A, Ferini-Strambi L, Dijkstra F, Viaene M, Abril B, Boeve BF; 23andMe Research Team; Scholz SW, Ryten M, Bandres-Ciga S, Noyce A, Cannon P, Pihlstrøm L, Nalls MA, Singleton AB, Rouleau GA, Postuma RB, Gan-Or Z. Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects. *Nat Commun*. 2022 Dec 5;13(1):7496. doi: 10.1038/s41467-022-34732-5. PMID: 36470867; PMCID: PMC9722930.
34. Camerucci E, Mullan AF, Bower JH, Bharucha AE, Turcano P, Stang CD, Benarroch EE, Boeve BF, Ahlskog JE, Savica R. Lifelong constipation in Parkinson's disease and other clinically defined alpha-synucleinopathies: A population-based study in Southeast Minnesota. *Parkinsonism Relat Disord*. 2022 Dec 22;107:105244. doi: 10.1016/j.parkreldis.2022.105244. Epub ahead of print. PMID: 36630736.
 35. Stefani A, Trenkwalder C, Arnulf I, Bliwise DL, Boeve BF, Inoue Y, Iranzo A, Lewis SJ, Provini F, Schenck C, Wenning GK, Wing YK, Hogl B, Videnovic A. Isolated rapid eye movement sleep behaviour disorder: clinical and research implications. *J Neurol Neurosurg Psychiatry*. 2023 Jul;94(7):581-582. doi: 10.1136/jnnp-2022-330913. Epub 2023 Mar 28. PMID: 36977554.
 36. Diaz-Galvan P, Miyagawa T, Przybelski SA, Lesnick TG, Senjem ML, Jack CR Jr, Forsberg LK, Min HK, St Louis EK, Savica R, Fields JA, Benarroch EE, Lowe V, Petersen RC, Boeve BF, Kantarci K. Brain glucose metabolism and nigrostriatal degeneration in isolated rapid eye movement sleep behaviour disorder. *Brain Commun*. 2023 Feb 2;5(1):fcad021. doi: 10.1093/braincomms/fcad021. PMID: 36844148; PMCID: PMC9945851.
 37. Elliott JE, Lim MM, Keil AT, Postuma RB, Pelletier A, Gagnon JF, St Louis EK, Forsberg LK, Fields JA, Huddlestone DE, Bliwise DL, Avidan AY, Howell MJ, Schenck CH, McLeland J, Criswell SR, Videnovic A, Durrin EH, Miglis MG, Shprecher DR, Lee-Iannotti JK, Boeve BF, Ju YS; North American Prodromal Synucleinopathy (NAPS) Consortium. Baseline characteristics of the North American prodromal Synucleinopathy cohort. *Ann Clin Transl Neurol*. 2023 Apr;10(4):520-535. doi: 10.1002/acn3.51738. Epub 2023 Feb 8. PMID: 36751940; PMCID: PMC10109527.
 38. Levendowski DJ, Neylan TC, Lee-Iannotti JK, Timm PC, Guevarra C, Angel E, Shprecher D, Mazeika G, Walsh CM, Boeve BF, St Louis EK. The Accuracy and Reliability of Sleep Staging and Sleep Biomarkers in Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder. *Nat Sci Sleep*. 2023 May 3;15:323-331. doi: 10.2147/NSS.S396853. PMID: 37162799; PMCID: PMC10164388.
 39. Liu G, Ni C, Zhan J, Li W, Luo J, Liao Z, Locascio JJ, Xian W, Chen L, Pei Z, Corvol JC, Maple-Grødem J, Campbell MC, Elbaz A, Lesage S, Brice A, Hung AY, Schwarzschild MA, Hayes MT, Wills AM, Ravina B, Shoulson I, Taba P, Köks S, Beach TG, Cormier-Dequaire F, Alves G, Tysnes OB, Perlmutter JS, Heutink P, van Hilten JJ, Barker RA, Williams-Gray CH, Scherzer CR; International Genetics of Parkinson Disease Progression (IGPP) Consortium. Mitochondrial haplogroups and cognitive progression in Parkinson's disease. *Brain*. 2023 Jan 5;146(1):42-49. doi: 10.1093/brain/awac327. PMID: 36343661
 40. Azami H, Moguilner S, Penagos H, Sarkis RA, Arnold SE, Gomperts SN, Lam AD. EEG Entropy in REM Sleep as a Physiologic Biomarker in Early Clinical Stages of Alzheimer's Disease. *J Alzheimers Dis*. 2023;91(4):1557-1572. doi: 10.3233/JAD-221152. PubMed PMID: 36641682; PubMed Central PMCID: PMC10039707.
 41. Zhou H, Li H, Gowravaram N, Quan M, Kausar N, Gomperts SN. Disruption of hippocampal neuronal circuit function depends upon behavioral state in the APP/PS1 mouse model of Alzheimer's disease. *Sci Rep*. 2022 Dec 5;12(1):21022. doi:

10.1038/s41598-022-25364-2. PubMed PMID: 36471155; PubMed Central PMCID: PMC9723144.

42. Heath L, Earls JC, Magis AT, Kornilov SA, Lovejoy JC, Funk CC, Rappaport N, Logsdon BA, Mangravite LM, Kunkle BW, Martin ER, Naj AC, Ertekin-Taner N, Golde TE, Hood L, Price ND; Alzheimer's Disease Genetics Consortium. Manifestations of Alzheimer's disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90. *Sci Rep.* 2022 Apr 12;12(1):6117. doi: 10.1038/s41598-022-09825-2
43. Scott GD, Neilson LE, Woltjer R, Quinn JF, Lim MM. Lifelong Association of Disorders Related to Military Trauma with Subsequent Parkinson's Disease. *Mov Disord.* 2023 Jun 13. doi: 10.1002/mds.29457. Online ahead of print.PMID: 37309872
44. Neilson LE, Quinn JF, Lim MM. Screening and Targeting Risk Factors for Prodromal Synucleinopathy: Taking Steps toward a Prescriptive Multi-modal Framework. *Aging Dis.* 2023 Jun 6. doi: 10.14336/AD.2022.1024. Online ahead of print.PMID: 37307836
45. Morris R, Martini DN, Kelly VE, Smulders K, Ramsey K, Hiller A, Chung KA, Hu SC, Zabetian CP, Poston KL, Mata IF, Edwards KL, Lapidus J, Cholerton B, Montine TJ, Quinn JF, Horak F. Gait and balance in apolipoprotein E4 allele carriers in older adults and Parkinson's disease. *Clin Park Relat Disord.* 2023 May 17;9:100201. doi: 10.1016/j.prdoa.2023.100201. eCollection 2023.PMID: 37252677
46. Boutros S.W., Zimmerman B., Nagy S.C., Unni V.K., Raber J. (2023). Age, sex, and apolipoprotein E isoform alter contextual fear learning, neuronal activation, and baseline DNA damage in the hippocampus. *Molecular Psychiatry* 2023 Feb 2. doi: 10.1038/s41380-023-01966-8. PMID: 36732588
47. Thurin K, Daffner K, Gale S, Donovan NJ, Urizar JC. Non-pharmacological treatments of neuropsychiatric symptoms in mild cognitive impairment. *Semin Neurol* 2022;42(02):192-203.
48. Ramamurthy A, Scharre D. Evaluation and management of delirium in dementia. *Curr Treat Options Neurol* 2022. DOI 10.1007/s11940-022-00721-8.
49. Ratcliff R, Scharre DW, McKoon G. Discriminating memory disordered patients from controls using diffusion model parameters from recognition memory. *J Exp Psychol Gen* 2022;151(6):1377-1393.
50. Thurin K, Patel V, Perez DL, et al. Case study 2: a 60-year-old man with progressive deficits in language output. *JNP* 2022;34(3):196-203.
51. Brumm MC, Siderowf A, Simuni T, Burghardt E, Choi SH, Caspell-Garcia C, Chahine LM, Mollenhauer B, Foroud T, Galasko D, Merchant K, Arnedo V, Hutten SJ, O'Grady AN, Poston KL, Tanner CM, Weintraub D, Kiebertz K, Marek K, Coffey CS; Parkinson's Progression Markers Initiative. Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson's Disease Progression. *J Parkinsons Dis.* 2023 Jul 12
52. Huynh HH, Kuch K, Orquillas A, Forrest K, Barahona-Carrillo L, Keene D, Henderson VW, Wagner AD, Poston KL, Montine TJ, Lin A, Tian L, MacCoss MJ, Emrick MA, Hoofnagle AN. Metrologically Traceable Quantification of 3 Apolipoprotein E Isoforms in Cerebrospinal Fluid. *Clin Chem.* 2023 Jun 6.
53. Morris R, Martini DN, Kelly VE, Smulders K, Ramsey K, Hiller A, Chung KA, Hu SC, Zabetian CP, Poston KL, Mata IF, Edwards KL, Lapidus J, Cholerton B, Montine TJ, Quinn JF, Horak F. "Gait and balance in apolipoprotein E4 allele carriers in older adults and Parkinson's disease." *Clin Park Relat Disord.* 2023 May 17;9:100201.
54. Fama R, Müller-Oehring EM, Levine TF, Sullivan EV, Sassoos SA, Asok P, Brontë-Stewart HM, Poston KL, Pohl KM, Pfefferbaum A, Schulte T. "Episodic memory deficit in HIV infection: common phenotype with Parkinson's disease, different neural substrates." *Brain Struct Funct.* 2023 Apr 18. (in press)
55. Phongpreecha T, Cholerton B, Bukhari S, Chang AL, De Francesco D, Thuraiappah M, Godrich D, Perna A, Becker MG, Ravindra NG, Espinosa C, Kim Y, Berson E, Mataraso S,

- Sha SJ, Fox EJ, Montine KS, Baker LD, Craft S, White L, Poston KL, Beecham G, Aghaeepour N, Montine TJ. "Prediction of neuropathologic lesions from clinical data." *Alzheimers Dement*. 2023 Jan 21. PMID: 36681388.
56. Endo M, Poston KL, Sullivan EV, Fei-Fei L, Pohl KM, Adeli E. "GaitForeMer: Self-Supervised Pre-Training of Transformers via Human Motion Forecasting for Few-Shot Gait Impairment Severity Estimation." *Med Image Comput Comput Assist Interv*. 2022 Sep;13438:130-139. doi: 10.1007/978-3-031-16452-1_13. PMID: 36342887
 57. Abdelnour C and Poston KL. Cognitive Impairment in Neurodegenerative Movement Disorders. *Semin Neurol*. 2023 Feb;43(1):81-94. doi: 10.1055/s-0043-1764204. Epub 2023 Mar 20. PMID: 36940727.
 58. Olfati, N., & Litvan, I. Understanding REM Sleep Behavior Disorder in Parkinson's Disease. *The New England journal of medicine*, 2022. 387(5), 480. <https://doi.org/10.1056/NEJMc2208067>
 59. Macchi ZA, Seshadri S, Ayele R, Bock M, Long J, Coats H, Miyasaki J, Pantilat SZ, Katz M, Santos EJ, Sillau SH, Lum HD, Kluger BM. Aggression Towards Caregivers in Parkinson's Disease and Related Disorders: A Mixed Methods Study. *Mov Disord Clin Pract*. 2022 Sep 7;9(7):920-931.
 60. Pelak VS, Mahmood A, Abe-Ridgway K. Perspectives and a Systematic Scoping Review on Longitudinal Profiles of Posterior Cortical Atrophy Syndrome. *Curr Neurol Neurosci Rep*. 2022 Nov;22(11):803-812.
 61. Holden SK, Bettcher BM, Filley CM, Lopez-Paniagua D, Pelak VS. Posterior white matter integrity and self-reported posterior cortical symptoms using the Colorado Posterior Cortical Questionnaire. *Frontiers in Neurology: Dementia and Neurodegenerative Diseases*. 2023 Feb 1;14:1072938.
 62. Abraham AG, Hong C, Deal JA, Bettcher BM, Pelak VS, Gross A, Jiang K, Swenor B, Wittich W. Are cognitive researchers ignoring their senses? The problem of sensory deficit in cognitive aging research. *J Am Geriatr Soc*. 2023 May;71(5):1369-1377.
 63. Ota Y, Kanel P, Bohnen N. Imaging of sleep disorders in pre-Parkinsonian syndromes. *Curr Opin Neurol*. 2022 Aug 1;35(4):443-452. doi: 10.1097/WCO.0000000000001084. Epub 2022 Jul 5. PMID: 35788559; PMCID: PMC9308698.
 64. Liao JY, Bohnen NI. Is heart rate variability the heart of the matter for freezing of gait? *Parkinsonism Relat Disord*. 2023 Jul 11:105763. doi: 10.1016/j.parkreldis.2023.105763. Epub ahead of print. PMID: 37468360.
 65. Roytman S, Paalanen R, Griggs A, David S, Pongmala C, Koeppe RA, Scott PJH, Marusic U, Kanel P, Bohnen NI. Cholinergic system correlates of postural control changes in Parkinson's disease freezers. *Brain*. 2023 Apr 22:awad134. doi: 10.1093/brain/awad134. Epub ahead of print. PMID: 37086478.
 66. Chou KL, Dayalu P, Koeppe RA, Gilman S, Spears CC, Albin RL, Kotagal V. Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease. *Mov Disord*. 2022 Nov;37(11):2301-2307. doi: 10.1002/mds.29220. Epub 2022 Sep 14. PMID: 36102173; PMCID: PMC9669145.
 67. Bohnen NI, Kanel P, Roytman S, Scott PJH, Koeppe RA, Albin RL, Kerber KA, Müller MLTM. Cholinergic brain network deficits associated with vestibular sensory conflict deficits in Parkinson's disease: correlation with postural and gait deficits. *J Neural Transm (Vienna)*. 2022 Aug;129(8):1001-1009. doi: 10.1007/s00702-022-02523-3. Epub 2022 Jun 26. PMID: 35753016; PMCID: PMC9308723.
 68. Doot RK, Young AJ, Nasrallah IM, Wetherill RR, Siderowf A, Mach RH, Dubroff JG. [18F]NOS PET Brain Imaging Suggests Elevated Neuroinflammation in Idiopathic Parkinson's Disease. *Cells*. 2022 Sep 30;11(19):3081. doi: 10.3390/cells11193081. PMID: 36231041; PMCID: PMC9563966
 69. Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA, Nguyen H, Alcalay RN, Chahine LM, Foroud T, Galasko D, Kiebertz K, Merchant K, Mollenhauer B,

- Poston KL, Seibyl J, Simuni T, Tanner CM, Weintraub D, Videnovic A, Choi SH, Kurth R, Caspell-Garcia C, Coffey CS, Frasier M, Oliveira LMA, Hutten SJ, Sherer T, Marek K, Soto C; Parkinson's Progression Markers Initiative. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α -synuclein seed amplification: across-sectional study. *Lancet Neurol.* 2023 May;22(5):407-417. doi:10.1016/S1474-4422(23)00109-6. PMID: 37059509
70. Rothlind JC, York MK, Luo P, Carlson K, Marks WJ Jr, Weaver FM, Stern M, Follett KA, Duda JE, Reda DJ; CSP-468 study group. Predictors of multi-domain cognitive decline following DBS for treatment of Parkinson's disease. *Parkinsonism Relat Disord.* 2022 Feb;95:23-27. doi: 10.1016/j.parkreldis.2021.12.011. Epub 2021 Dec 18. PMID: 34974395. 2023 Jan-Mar;37(1):50-58. doi: 10.1097/WAD.0000000000000545. Epub 2023 Feb 23.
 71. Struzyna LA, Browne KD, Burrell JC, Vélez WJG, Wofford KL, Kaplan HM, Murthy NS, Chen HI, Duda JE, España RA, Cullen DK. Axonal Tract Reconstruction Using a Tissue-Engineered Nigrostriatal Pathway in a Rat Model of Parkinson's Disease. *Int J Mol Sci.* 2022 Nov 12;23(22):13985. doi: 0.3390/ijms232213985. PMID: 36430464; PMCID: PMC9692781.
 72. Nilsson J, Cousins K, Gobom J, Portelius E, Chen-Plotkin A, Shaw LM, Grossman M, Irwin DJ, Trojanowski JQ, Zetterberg H, Blennow K, Brinkmalm A. Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders. *Alzheimers Dement.* 2023 May;19(5):1775-1784. doi: 10.1002/alz.12809. Epub 2022 Oct 14. PMID: 36239248; PMCID: PMC10102247.
 73. Vaswani PA, Morley JF, Jennings D, Siderowf A, Marek K; PARS Investigators. Predictive value of abbreviated olfactory tests in prodromal Parkinson disease. *NPJ Parkinsons Dis.* 2023 Jun 29;9(1):103. doi: 10.1038/s41531-023-00530-z. PMID: 37386033; PMCID: PMC10310835.
 74. Brumm MC, Siderowf A, Simuni T, Burghardt E, Choi SH, Caspell-Garcia C, Chahine LM, Mollenhauer B, Foroud T, Galasko D, Merchant K, Arnedo V, Hutten SJ, O'Grady AN, Poston KL, Tanner CM, Weintraub D, Kiebertz K, Marek K, Coffey CS; Parkinson's Progression Markers Initiative. Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson's Disease Progression. *J Parkinsons Dis.* 2023 Jul 12. doi: 10.3233/JPD-223433. Epub ahead of print. PMID: 37458046.
 75. DeCourt B, Sabbagh MN. The importance of genomics in advancing the treatment of dementia, *Lancet Neurology* 2022 Published online June 10, 2022, [https://doi.org/10.1016/S1474-4422\(22\)00234-4](https://doi.org/10.1016/S1474-4422(22)00234-4)
 76. Pahwa R, Isaacson SH, Small GW, Torres-Yaghi Y, Pagan F, Sabbagh M. Screening, Diagnosis, and Management of Parkinson's Disease Psychosis: Recommendations From an Expert Panel *Neurol Ther.* 2022 Jul 29. doi: 10.1007/s40120-022-00388-y. Online ahead of print
 77. Marwan Sabbagh, Gary W. Small, Stuart H. Isaacson, Yasar Torres-Yaghi, Fernando Pagan & Rajesh Pahwa (2022) Unmet needs in the diagnosis and treatment of Parkinson's disease psychosis and dementia-related psychosis, *International Journal of Psychiatry in Clinical Practice*, DOI: 10.1080/13651501.2022.2058406
 78. Langley J, Hwang K, Hu X, Huddleston DE. Nigral volumetric and microstructural measures in individuals with scans without evidence of dopaminergic deficit. *Frontiers in Neuroscience.* (2022) Nov 24; 16. doi: 10.3389/fnins.2022.1048945
 79. Adrissi J, Fleisher J. Moving the Dial Toward Equity in Parkinson's Disease Clinical Research: a Review of Current Literature and Future Directions in Diversifying PD Clinical Trial Participation. *Curr Neurol Neurosci Rep.* 2022 Aug;22(8):475-483. doi: 10.1007/s11910-022-01212-8. Epub 2022 Jun 17. PMID: 35713775; PMCID: PMC9578442

80. Mehanna R, Smilowska K, Fleisher J, Post B, Hatano T, Pimentel Piemonte ME, Kumar KR, McConvey V, Zhang B, Tan EK, Savica R; International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson's Disease. Age Cutoff for Early-Onset Parkinson's Disease: Recommendations from the International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson's Disease. *Mov Disord Clin Pract*. 2022 Sep 10;9(7):869-878. doi: 10.1002/mdc3.13523. PMID: 36247919; PMCID: PMC9547138.
81. Fleisher JE, Hess SP, Klostermann EC, Lee J, Myrick E, Mitchem D, Niemet C, Woo K, Sennott BJ, Sanghvi M, Witek N, Beck JC, Wilkinson JR, Ouyang B, Hall DA, Chodosh J. IN-HOME-PD: The effects of longitudinal telehealth-enhanced interdisciplinary home visits on care and quality of life for homebound individuals with Parkinson's disease. *Parkinsonism Relat Disord*. 2022 Sep;102:68-76. doi: 10.1016/j.parkreldis.2022.07.017. Epub 2022 Aug 7. PMID: 35963046; PMCID: PMC9578443.
82. Fleisher JE, Suresh M, Klostermann EC, Lee J, Hess SP, Myrick E, Mitchem D, Woo K, Sennott BJ, Witek NP, Chen SM, Beck JC, Ouyang B, Wilkinson JR, Hall DA, Chodosh J. IN-HOME-PDCaregivers: The effects of a combined home visit and peer mentoring intervention for caregivers of homebound individuals with advanced Parkinson's disease. *Parkinsonism Relat Disord*. 2023 Jan;106:105222. doi: 10.1016/j.parkreldis.2022.11.014. Epub 2022 Nov 17. PMID: 36446676; PMCID: PMC9825655.
83. Olvera CE, Fleisher JE, Kramer NM. Motor Complications and Treatment in Advanced Parkinson's Disease #456. *J Palliat Med*. 2023 May;26(5):730-731. doi: 10.1089/jpm.2023.0046. PMID: 37130285. Also available at: <https://www.mypcnow.org>
84. Shah-Zamora D, Anderson S, Barton B, Fleisher JE. Virtual Group Music Therapy for Apathy in Parkinson's Disease: A Pilot Study. *J Geriatr Psychiatry Neurol*. 2023 May 18:8919887231176755. doi: 10.1177/08919887231176755. Epub ahead of print. PMID: 37201184.
85. Olvera CE, Levin ME, Fleisher JE. Chapter 4 - Community-based neuropalliative care. In: Miyasaki JM, Kluger BM, eds. *Handbook of Clinical Neurology*. Vol 191. Neuropalliative Care. Elsevier; 2023:49-66. doi:10.1016/B978-0-12-824535-4.00001-X. PMID: 36599515.
86. Nutakki A, Bobat HI, Kolala K, Haketa MM, Mwelwa P, Darji D, Kumar JSJ, Bobat MA, Sinha V, Sinha V, Kennedy C, Bailey FA, Fleisher JE, Mataa M, Saylor D. Perceptions of and Preferences for Patient-Physician Communication at the University Teaching Hospital in Lusaka, Zambia. Under review, *Journal of General Internal Medicine*, 2023.
87. Smilowska K, Post B, Fleisher JE, Mehanna R, Jackson L, Pimentel Piemonte ME, Savica R. Unmet need in early onset Parkinson's disease: Deep Brain Stimulation and Pregnancy. Under review, *Journal of Parkinson's Disease*, 2023.
88. Beghi E, Ivashynka A, Logroscino G, Ferreira de Oliveira F, Fleisher JE, Kim YJJ, Dumitrascu OM, Patel R, Savica R. The COVID-19 pandemic and the nervous system: A critical appraisal of the current evidence and future directions. Under review, *The Neurologist*, 2023.
89. Fleisher JE, Woo K, Chodosh J. The Interdisciplinary Home Visit Program for Individuals with Advanced Parkinson's Disease. In: *Geriatric Models of Care (Second edition)*, Malone M, Boltz M, Macias Tejada J, and White H (Ed), Springer Nature, Berlin, Germany, under review, 2024.
90. Bellenguez, C., Kucukali, F., Jansen, I. E., Kleindam, L., Moreno-Grau, S., Amin, N., Naj, A. C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., Holmans, P. A., . . . Lambert, J. C. New insights into the genetic etiology of Alzheimer's disease and related dementias. *Nat Genet*, 2022. 54(4), 412-436. <https://doi.org/10.1038/s41588-022-01024-z>
91. Honig, L. S., Kang, M. S., Lee, A. J., Reyes-Dumeyer, D., Piriz, A., Soriano, B., Franco, Y., Coronado, Z. D., Recio, P., Mejia, D. R., Medrano, M., Lantigua, R. A., Teich, A. F., Dage, J. L., & Mayeux, R. Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer

- Disease Among Adults of Caribbean Hispanic Ethnicity. *JAMA Netw Open*, 2023. 6(4), e238214. <https://doi.org/10.1001/jamanetworkopen.2023.8214>
92. Pal, G., Cook, L., Schulze, J., Verbrugge, J., Alcalay, R. N., Merello, M., Sue, C. M., Bardien, S., Bonifati, V., Chung, S. J., Foroud, T., Gatto, E., Hall, A., Hattori, N., Lynch, T., Marder, K., Mascazoni, D., Novakovic, I., Thaler, A., . . . Klein, C. Genetic Testing in Parkinson's Disease. *Mov Disord*. 2023. <https://doi.org/10.1002/mds.29500>
 93. Ryvicker, M., Barron, Y., Shah, S., Moore, S. M., Noble, J. M., Bowles, K. H., & Merrill, J. Clinical and Demographic Profiles of Home Care Patients With Alzheimer's Disease and Related Dementias: Implications for Information Transfer Across Care Settings. *J Appl Gerontol*, 2022. 41(2), 534-544. <https://doi.org/10.1177/0733464821999225>
 94. Padmanabhan P, Casamento-Moran A, Kim A, Gonzalez AJ, Pantelyat A, Roemmich RT, Chib VS. Dopamine facilitates the translation of physical exertion into assessments of effort. *NPJ Parkinsons Dis*. 2023 Apr 1;9(1):51. doi: 10.1038/s41531-023-00490-4. PMID: 37005418; PMCID: PMC10067851.
 95. Jang Y, Pletnikova O, Troncoso JC, Pantelyat AY, Dawson TM, Rosenthal LS, Na CH. Mass Spectrometry-Based Proteomics Analysis of Human Substantia Nigra From Parkinson's Disease Patients Identifies Multiple Pathways Potentially Involved in the Disease. *Mol Cell Proteomics*. 2023 Jan;22(1):100452. doi: 10.1016/j.mcpro.2022.100452. Epub 2022 Nov 22. Erratum in: *Mol Cell Proteomics*. 2023 Jun;22(6):100570. PMID: 36423813; PMCID: PMC9792365.
 96. Dewey DC, Chitnis S, McCreary MC, Gerald A, Dewey CH, Pantelyat A, Dawson TM, Rosenthal LS, Dewey RB Jr. APDM gait and balance measures fail to predict symptom progression rate in Parkinson's disease. *Front Neurol*. 2022 Nov 9;13:1041014. doi: 10.3389/fneur.2022.1041014. PMID: 36438964; PMCID: PMC9681812.
 97. Butala A, Li K, Swaminathan A, Dunlop S, Salnikova Y, Ficek B, Portnoff B, Harper M, Vernon B, Turk B, Mari Z, Pantelyat A. Parkinsonics: A Randomized, Blinded, Cross-Over Trial of Group Singing for Motor and Nonmotor Symptoms in Idiopathic Parkinson Disease. *Parkinsons Dis*. 2022 Sep 20;2022:4233203. doi: 10.1155/2022/4233203. PMID: 36247106; PMCID: PMC9553721.
 98. Wang S, Unnithan S, Bryant N, Chang A, Rosenthal LS, Pantelyat A, Dawson TM, Al-Khalidi HR, West AB. Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease. *Mov Disord*. 2022 Jul;37(7):1454-1464. doi: 10.1002/mds.29043. Epub 2022 May 6. PMID: 35521944; PMCID: PMC9308673.
 99. Stegemoller E, Forsyth E, Patel B, Elkouzi A. Group therapeutic singing improves clinical motor scores in persons with Parkinson's disease. *BMJ Neurol Open*. 2022;4(2):e000286. Published 2022 Aug 3. doi:10.1136/bmjno-2022-000286
 100. Patterson CG, Joslin E, Gil AB, Spigle W, Nemet T, Chahine L, Christiansen CL, Melanson E, Kohrt WM, Mancini M, Josbeno D, Balfany K, Griffith G, Dunlap MK, Lamotte G, Suttman E, Larson D, Branson C, McKee KE, Goelz L, Poon C, Tilley B, Kang UJ, Tansey MG, Luthra N, Tanner CM, Haus JM, Fantuzzi G, McFarland NR, Gonzalez-Latapi P, Foroud T, Motl R, Schwarzschild MA, Simuni T, Marek K, Naito A, Lungu C, Corcos DM; SPARX3-PSG Investigators. Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial. *Trials*. 2022;23(1):855. Published 2022 Oct 6. doi:10.1186/s13063-022-06703-0
 101. Wollney EN, Armstrong MJ, Bedenfield N, Rosselli M, Curiel-Cid RE, Kitaigorodsky M, Levy X, Bylund CL. Barriers and Best Practices in Disclosing a Dementia Diagnosis: A Clinician Interview Study. *Health Serv Insights*. 2022;15:11786329221141829. Published 2022 Dec 5. doi:10.1177/11786329221141829
 102. Alipour-Haris G, Armstrong MJ, Okun M, Brown JD. Comparison of Pimavanserin Versus Quetiapine for Hospitalization and Mortality Risk Among Medicare Beneficiaries with Parkinson's Disease Psychosis. *Mov Disord Clin Pract*. 2023;10(3):406-414. Published 2023 Jan 10. doi:10.1002/mdc3.13652

103. Richards K, Brown C, Johnsrud M, Arcona S, Sasane R, Armstrong MJ, Feuerstein J, Shill H, Talman L, Mantri S. Perspectives on Parkinson's Disease Medications: A Qualitative Study of People with Parkinson's Disease (P14-11.015). *Neurolog.* 2023;100:14-11.015. Published 2023 Apr 28 [abstract]. doi:10.1212/WNL.0000000000202791
104. Wilkes BJ, Tobin ER, Arpin DJ, Wang WE, Okun MS, Jaffee MS, McFarland NR, Corcos DM, Vaillancourt DE. Distinct cortical and subcortical predictors of Purdue Pegboard decline in Parkinson's disease and atypical parkinsonism. *NPJ Parkinsons Dis.* 2023;9(1):85. Published 2023 Jun 5. doi:10.1038/s41531-023-00521-0
105. Fowler King B, MacDonald J, Stoff L, Nettnin E, Jayarman A, Goldman JG, Rafferty M. Activity Monitoring in Parkinson Disease: A Qualitative Study of Implementation Determinants. *J Neurol Phys Ther.* 2023 Jun 12. doi: 10.1097/NPT.0000000000000451. Epub ahead of print. PMID: 37306418.
106. Goldman JG, Merkitch D, Brewington D, Peirce H, Rho M, Jayabalan P, Curran J, Brennan K. Patient experiences receiving rehabilitation care via telehealth: Identifying opportunities for remote care. *Front Rehabil Sci.* 2023 Feb 2;4:1049554. doi: 10.3389/fresc.2023.1049554. PMID: 36817717; PMCID: PMC9932031.
107. Williams GP, Muskat K, Frazier A, Xu Y, Mateus J, Grifoni A, da Silva Antunes R, Weiskopf D, Amara AW, Standaert DG, Goldman JG, Litvan I, Alcalay RN, Sulzer D, Lindestam Arlehamn CS, Sette A. Unaltered T cell responses to common antigens in individuals with Parkinson's disease. *J Neurol Sci.* 2023 Jan 15;444:120510. doi: 10.1016/j.jns.2022.120510. Epub 2022 Nov 25. PMID: 36495691; PMCID: PMC9950758.
108. Valentijn PP, Eggers C, Bloem BR, Grimes D, Goldman J, McGinley J, Gardner J, Piemonte MEP, Dahodwala N, Brennan L, Iansek R, Kovacs N, Parashos S, Hilel A, Rajan R; MDS Study Group on Management of Movement Disorders: Interdisciplinary and Integrated Care. Validation of the Rainbow Model of Integrated Care Measurement Tool in Parkinson's Disease. *Mov Disord.* 2023 Jul;38(7):1253-1261. doi: 10.1002/mds.29413. Epub 2023 May 6. PMID: 37148424.
109. Digma LA, Litvan I, del Ser T, Bayram E. Sex differences for cognitive decline in progressive supranuclear palsy. *Parkinsonism Relat Disord.* 2023. doi: 10.1016/j.parkreldis.2023.105454
110. Sreenivasan K, Bayram E, Zhuang X, Longhurst J, Yang Z, Cordes D, Ritter A, Caldwell J, Cummings JL, Mari Z, Litvan I, Bluett B, Mishra VR. Topological Reorganization of Functional Hubs in Patients with Parkinson's Disease with Freezing of Gait. *J Neuroimaging.* 2023. doi: 10.1111/jon.13107
111. Bayram E*, Batzu L*, Tilley B*, Gandhi R, Jagota P, Biundo R, Garon M, Prasertpan T, Lazcano-Ocampo C, Chaudhuri R, Weil RS, on behalf of the International Parkinson and Movement Disorder Society Non-Motor Parkinson's Disease Study Group. Clinical trials for cognition in Parkinson's disease: Where are we and how can we do better? *Parkinsonism Relat Disord.* 2023 Mar 29, 105385. doi: 10.1016/j.parkreldis.2023.105385 (*these authors contributed equally)
112. Bayram E, Weigand AJ, Flatt JD. Perceived Discrimination in Healthcare for LGBTQIA+ People Living with Parkinson's Disease. *J Gerontol B Psychol Sci Soc Sci.* 2023 Mar 10;gbad046. doi: 10.1093/geronb/gbad046.
113. Olfati N, Ghodsi H, Bayram E, Litvan I. Why Therapeutic Trials Fail in Primary Tauopathies. *Mov Disord.* 2023. doi: 10.1002/mds.29322.
114. Donahue EK, Venkadesh S, Bui V, Cabrera Tuazon A, Wang RK, Haase D, Foreman RP, Duran JJ, Petkus A, Wing D, Higgins M, Holschneider DP, Bayram E, Litvan I, Jakowec MW, Darrell Van Horn J, Schiehser DM, Petzinger GM. Physical activity intensity is associated with cognition and functional connectivity in Parkinson's disease. *Parkinsonism Relat Disord.* 2022,104:7-14. doi: 10.1016/j.parkreldis.2022.09.005

